Factors associated with mortality in transplant patients with invasive aspergillosis.
暂无分享,去创建一个
E. Anaissie | O. Williams | B. Alexander | J. Baddley | J. Wingard | J. Ito | D. Kontoyiannis | T. Walsh | D. Andes | T. Chiller | T. Chiller | K. Marr | R. Oster | T. Patterson | P. Pappas | C. Kauffman | M. Schuster | P. Pappas | David R. Andes | Thomas J. Walsh | Carol A. Kauffman | Thomas F Patterson | D. P. Kontoyiannis | Barbara D. Alexander | Robert A. Oster | E. Anaissie | Mindy G. Schuster | James I. Ito | O. Dale Williams | Thomas F. Patterson
[1] A. Glasmacher,et al. Overall survival and fungal infection-related mortality in patients with invasive fungal infection and neutropenia after myelosuppressive chemotherapy in a tertiary care centre from 1995 to 2006 , 2010, The Journal of antimicrobial chemotherapy.
[2] J. Sierra,et al. Predicting survival in adults with invasive aspergillosis during therapy for hematological malignancies or after hematopoietic stem cell transplantation: Single‐center analysis and validation of the Seattle, French, and Strasbourg prognostic indexes , 2009, American journal of hematology/oncology.
[3] Philippe Lutun,et al. Factors associated with overall and attributable mortality in invasive aspergillosis. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[4] J. Perfect,et al. Defining responses to therapy and study outcomes in clinical trials of invasive fungal diseases: Mycoses Study Group and European Organization for Research and Treatment of Cancer consensus criteria. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[5] Y. Taur,et al. Risk factors and attributable mortality of late aspergillosis after T‐cell depleted hematopoietic stem cell transplantation , 2008, Transplant infectious disease : an official journal of the Transplantation Society.
[6] J. Wingard,et al. Changes in causes of death over time after treatment for invasive aspergillosis , 2008, Cancer.
[7] Raoul Herbrecht,et al. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[8] L. Pagano,et al. Fungal infections in recipients of hematopoietic stem cell transplants: results of the SEIFEM B-2004 study--Sorveglianza Epidemiologica Infezioni Fungine Nelle Emopatie Maligne. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[9] N. Milman,et al. Aspergillus infection in lung transplant patients: incidence and prognosis , 2007, European Journal of Clinical Microbiology & Infectious Diseases.
[10] G. Rutherford,et al. Estimating Severe Coccidioidomycosis in California , 2007, Emerging infectious diseases.
[11] C. Heussel,et al. Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial). , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[12] M. Boeckh,et al. Invasive aspergillosis following hematopoietic cell transplantation: outcomes and prognostic factors associated with mortality. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[13] Raoul Herbrecht,et al. Imaging findings in acute invasive pulmonary aspergillosis: clinical significance of the halo sign. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[14] J. Fine,et al. Diagnosis of invasive aspergillosis using a galactomannan assay: a meta-analysis. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[15] C. Cordonnier,et al. Prognostic factors for death due to invasive aspergillosis after hematopoietic stem cell transplantation: a 1-year retrospective study of consecutive patients at French transplantation centers. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[16] G. Klintmalm,et al. Combination of Voriconazole and Caspofungin as Primary Therapy for Invasive Aspergillosis in Solid Organ Transplant Recipients: A Prospective, Multicenter, Observational Study , 2006, Transplantation.
[17] M. Boeckh,et al. Combination antifungal therapy for invasive aspergillosis. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[18] Russell E. Lewis,et al. Efficacy and toxicity of caspofungin in combination with liposomal amphotericin B as primary or salvage treatment of invasive aspergillosis in patients with hematologic malignancies , 2003, Cancer.
[19] Richard Sylvester,et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. , 2002, The New England journal of medicine.
[20] Lawrence Corey,et al. Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[21] J. Latgé,et al. Survival and prognostic factors of invasive aspergillosis after allogeneic bone marrow transplantation. , 1999, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[22] W. Leisenring,et al. Epidemiology of Aspergillus infections in a large cohort of patients undergoing bone marrow transplantation. , 1997, The Journal of infectious diseases.
[23] J. Perfect,et al. Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[24] G. Maschmeyer,et al. Invasive aspergillosis: epidemiology, diagnosis and management in immunocompromised patients. , 2007, Drugs.
[25] L. Pagano,et al. Design and Methods , 2022 .
[26] J. Baddley,et al. Antifungal combination therapy: clinical potential. , 2005, Drugs.
[27] K. Wannemuehler,et al. Incidence of invasive aspergillosis following hematopoietic stem cell and solid organ transplantation: interim results of a prospective multicenter surveillance program. , 2005, Medical mycology.
[28] D. Denning,et al. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.